Clinical Trials

Herbal medicinal product, dedicated primary for treatment of different cancer types.

Clinical trial on terapeutic efficacy, tolerability and safety of peroral solutions varumin® 1 and 2 (Inter-Evrogeneks) in a combined treatment with polyvitamin – antioxidative therapy in patients with biologicaly (PCR) detected HPV infection of high-risk type, with or without biopticaly verified CIN I.

University Gynecology and Obstetrics Clinic, Vodnjanska bb, University St. Cyrillus and Methodius, Skopje, Macedonia

Varumin® is new hope for all MULTIPLE SCLEROSIS (MS) patients.

One small, but still significant study made some time ago, undoubtedly has proven that immuno-modulatory effect of Varumin® acts hepful in treatment of this ilness.
“Inter-evrogeneks” goes on with promotion of the first product ever, which managed complete elimination of presence of all signs characteristical for MS.

Topic of the study is: Clinical examination of therapeutical efficacy, tolerance and safety of Varumin® in patients with molecular biology (PCR) proven HPV infection typed with high risk, with and without bioptical proven CIN. Until now, results are in favur of expectations.

This first statistical cut is the beginning of wave that will give scientific approval to all indications claimed about Varumin® during all these years. Varumin® therapy will be first-choice therapy in all conditions characterized with compromised immunity.